Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Soluble Denosumab Microneedle Patches
NCT07085520Phase 1Not yet recruiting
- Start
- Jul 2025
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of denosumab in osteoporosis and osteoarthritis (OA) (4 arms). Primary endpoints: Number of Participants With Adverse Reactions at 2 weeks, Amount of pain at 2 weeks and 1 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosisosteoarthritis (OA)
Beyond the preview
Go deeper on NCT07085520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085520.